Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Rises: Daily Dose
Your daily dose of the clinical news you may have missed.
Exercise of Any Level Linked to Reduced All-Cause Mortality in Individuals with Dementia
Physical activity of any level before and after a diagnosis of dementia was associated with at least a 20% lower risk for all-cause mortality across dementia subtypes.
ECLIPSE Trial of Cell-Free DNA Blood-Based CRC Screening Test: Expert Overview
William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.
The Liver Meeting 2024: Bausch Health Presents Phase 3 Study Design for Investigational Rifaximin Formulation to Delay OHE
The RED-C clinical trial program highlights the promising potential of the rifaximin soluble solid dispersion immediate-release tablets for delaying early HE-related decompensation.
2025 GOLD Report for COPD: MeiLan Han, MD, MS, Discusses Addition of Dupilumab, Ensifentrine
The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.
Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data
Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.
Awareness of Lung Cancer Screening Extremely Low Among Those at Highest Risk in the US: New Data
Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.
Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes
AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.
Agitation in Alzheimer Disease and Antipsychotics Used Off-Label are Not Meant for Each Other
Antipsychotic medications are still used to treat potentially harmful acute agitation, George Grossberg, MD, explains, even though the adverse effects are well known.
Aprocitentan Now Available in the US for Treatment-Resistant Hypertension
Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.
FDA Accepts Dupilumab sBLA for Review for Treatment of Chronic Spontaneous Urticaria
The target action date for the FDA decision is April 18, 2025, according to Sanofi and Regeneron.
European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population
The EMA recommendation excludes from treatment adults who are homozygous for the ApoE ε4 gene, a decision that the US Alzheimer's Association does not support, said the president/CEO.
Risk Factors for Type 1 Diabetes: A Snapshot for Primary Care
About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.
Semaglutide 2.4 mg Cuts Hospitalization Risk in CVD, Obesity: Daily Dose
Nonpharmacologic Options for Agitation in Alzheimer Disease Should Always Come First: Expert Insights
Nondrug approaches to calming an adult with Alzheimer disease who is agitated should be prioritized over pharmacotherapy, geriatric psychiatrist George Grossberg, MD, counsels.
Environment is a Primary Nonpharmacologic Intervention to Reduce Agitation in Alzheimer Disease, Geriatric Psychiatrist Explains
When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.
World Diabetes Day 2024: Diabetes Facts & Stats & a Call to Act
A quick review of the scope of diabetes in the US and of the gaps in equitable access to care supports the annual call to action from the International Diabetes Federation.
7 Questions on US STI Trends
The CDC just released its annual STD surveillance report. Are you caught up on the latest trends? Try your hand at these 7 questions to find out.
GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose
STI Epidemic in US Shows Signs of Slowing, According to New CDC Report
More than 2.4 million STIs were reported in the US in 2023 — a 1.8% decrease from 2022, according to the CDC's annual STI report.
